DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cbdpzz/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering.
The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen.
For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action.
'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field.
Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation.
Key Topics Covered:
1. Introduction, scopes and objectives
2. Antibody conjugates and other payloads
3. Linker technologies
4. Payload platforms
5. Improving payload delivery mechanisms
6. IP challenges, deal structures, mergers and acquisitions; future opportunities
7. Interviews with experts in the field
- ADC Therapeutics
- AREVA Med
- Actinium Pharmaceuticals
- Alpha Cancer Technologies
- Asana Biosciences
- Aspyrian Therapeutics
- BiOasis Technologies
- Biogen Idec
- Boehringer Ingelheim
- Cancer Research UK
- Cellerant Therapeutics
For more information visit http://www.researchandmarkets.com/research/cbdpzz/intelligence_on